Search research articles
Contact Us
Filters
Showing results (1-10 of 59) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
March 18, 2006
Epidemic Clostridium difficile
Mark H Wilcox, Jane Freeman
Infectious Disease Clinics of North America
|
January 14, 2015
Predictive values of models of Clostridium difficile infection
Caroline H Chilton, Jane Freeman
The Journal of Antimicrobial Chemotherapy
|
April 30, 2005
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
Simon D Baines, Jane Freeman, Mark H Wilcox
The Journal of Antimicrobial Chemotherapy
|
May 31, 2003
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut
Jane Freeman, Fiona J O'Neill, Mark H Wilcox
Lancet (London, England)
|
March 28, 2006
Measurement of toxin production by Clostridium difficile
Jane Freeman, Warren Fawley, Simon Baines, et al.
Gut Microbes
|
May 5, 2012
Models for the study of Clostridium difficile infection
Emma L Best, Jane Freeman, Mark H Wilcox
Pediatric Neurosurgery
|
April 26, 2006
CSF shunt failure with stable normal ventricular size
Ken R Winston, John A Lopez, Jane Freeman
Antimicrobial Agents and Chemotherapy
|
February 19, 2009
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection
Simon D Baines, Jane Freeman, Mark H Wilcox
Antimicrobial Agents and Chemotherapy
|
December 21, 2016
<i>In Vitro</i> Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
Jane Freeman, Sally Pilling, Jonathan Vernon, et al.
Antimicrobial Agents and Chemotherapy
|
November 11, 2015
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
Jane Freeman, Jonathan Vernon, Richard Vickers, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 59) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
March 18, 2006
Epidemic Clostridium difficile
Mark H Wilcox, Jane Freeman
Infectious Disease Clinics of North America
|
January 14, 2015
Predictive values of models of Clostridium difficile infection
Caroline H Chilton, Jane Freeman
The Journal of Antimicrobial Chemotherapy
|
April 30, 2005
Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model
Simon D Baines, Jane Freeman, Mark H Wilcox
The Journal of Antimicrobial Chemotherapy
|
May 31, 2003
Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut
Jane Freeman, Fiona J O'Neill, Mark H Wilcox
Lancet (London, England)
|
March 28, 2006
Measurement of toxin production by Clostridium difficile
Jane Freeman, Warren Fawley, Simon Baines, et al.
Gut Microbes
|
May 5, 2012
Models for the study of Clostridium difficile infection
Emma L Best, Jane Freeman, Mark H Wilcox
Pediatric Neurosurgery
|
April 26, 2006
CSF shunt failure with stable normal ventricular size
Ken R Winston, John A Lopez, Jane Freeman
Antimicrobial Agents and Chemotherapy
|
February 19, 2009
Tolevamer is not efficacious in the neutralization of cytotoxin in a human gut model of Clostridium difficile infection
Simon D Baines, Jane Freeman, Mark H Wilcox
Antimicrobial Agents and Chemotherapy
|
December 21, 2016
<i>In Vitro</i> Activities of MCB3681 and Eight Comparators against Clostridium difficile Isolates with Known Ribotypes and Diverse Geographical Spread
Jane Freeman, Sally Pilling, Jonathan Vernon, et al.
Antimicrobial Agents and Chemotherapy
|
November 11, 2015
Susceptibility of Clostridium difficile Isolates of Varying Antimicrobial Resistance Phenotypes to SMT19969 and 11 Comparators
Jane Freeman, Jonathan Vernon, Richard Vickers, et al.
Page
of 6